<p>Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis</p>-Reference-Cited by-同舟云学术

Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis

Published:2020-09 Issue: Volume:Volume 15 Page:2199-2206
ISSN:1178-2005
Container-title:International Journal of Chronic Obstructive Pulmonary Disease
language:en
Short-container-title:COPD

Author:

Watz Henrik,Rickard Kathleen^ORCID,Rheault Tara,Bengtsson Thomas,Singh Dave

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pulmonary and Respiratory Medicine,General Medicine

Reference19 articles.

1. Prevalence and Burden of Dyspnoea Among Patients with Chronic Obstructive Pulmonary Disease in Five European Countries

2. Symptom variability in patients with severe COPD: a pan-European cross-sectional study

3. Greater dyspnea is associated with lower health-related quality of life among European patients with COPD

4. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease

5. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease;Trends in Pharmacological Sciences;2024-09

2. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials);American Journal of Respiratory and Critical Care Medicine;2023-08-15

3. Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD;International Journal of Chronic Obstructive Pulmonary Disease;2023-07

4. Recent advances predict a bright future for nebulizers;Current Opinion in Pulmonary Medicine;2023-01-09

5. CFTR Modulator Therapy for Rare CFTR Mutants;Journal of Respiration;2022-04-05